RxDoctor Payments Data
★ My doctorsLook up a doctor →

Nighat Mehdi

Pediatric Pulmonology · Oklahoma City, OKNPI 1063480382

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,199 of the $1,734 with a category attached, or 69.1%. AstraZeneca accounts for 90.5% of it on its own, with 2 other manufacturers making up the rest.

$1,734in general payments, 2019–2025

Across 11 payments — averaging $157.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Vertex$147
  • Vivus LLC$18
$746,884in research payments, 2019–2025

Across 45 payments — averaging $16,597 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$639K
  • Astrazeneca UK Limited$87K
  • AbbVie$17K
  • Mylan Inc.$4K
  • Vivus LLC$652
  • Novartis$6

What the payments were for

  • Travel & lodging$1,19969%
  • Food & beverage$53531%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca8$1,570
Vertex2$147
Vivus LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric pulmonology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Other pediatric pulmonology in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →